GlassScriptPhysician profile
Rafael Perez
NPI 1528004579
$14,050.14
in general payments reported to CMS, 2019-2025
27 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $251 · 2021: $3,289 · 2022: $3,423 · 2023: $4,353 · 2024: $519 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,034 · Education: $1,533 · Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,034.00 |
| Education | $1,532.62 |
| Food and Beverage | $935.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,145.54 | 2019-2023 | |
| Intuitive Surgical, INC. | $5,815.61 | 2022-2025 | |
| Caldera Medical, INC | $531.23 | 2022-2024 | Desara |
| Femselect INC. | $239.50 | 2024 | Enplace |
| Axonics, INC. | $183.04 | 2020-2021 | |
| Pfizer INC. | $143.20 | 2020-2023 | |
| Amgen INC. | $111.10 | 2019 | |
| Amag Pharmaceuticals, INC. | $104.96 | 2019-2021 | |
| Medtronic, INC. | $90.21 | 2022 | |
| Therapeuticsmd, INC. | $77.30 | 2019-2020 | |
| Myovant Sciences INC. | $76.68 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $73.94 | 2024-2025 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $69.19 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $67.73 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $59.77 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.81 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $45.81 | 2019 | |
| Innovation Technologies INC | $37.57 | 2024 | Irrisept |
| Urovant Sciences INC | $19.58 | 2022 | |
| Bolder Surgical LLC | $16.79 | 2019 | |
| Duchesnay USA Incorporated | $15.44 | 2019 | |
| Evoke Pharma, INC. | $15.29 | 2023 | Gimoti |
| Coloplast Corp | $14.60 | 2021 | |
| Mission Pharmacal Company | $14.45 | 2021 | |
| Millicent US INC | $13.35 | 2024 | |
| Dysis Medical, INC. | $12.45 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.